Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

Haematologica

Volumn 92, Issue 1, 2007, Pages 135-136

  Finazzi, Guido ^a   Rambaldi, Alessandro ^a   Guerini, Vittoria ^a   Carobbo, Alessandra ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Essential thrombocythemia; JAK2 mutation; Polycythemia vera; Thrombosis

Indexed keywords

JANUS KINASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; SCHOOL CHILD; THROMBOCYTHEMIA; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; RISK; THROMBOCYTOPENIA; THROMBOSIS;

EID: 33846896185     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10634     Document Type: Article

References (7)

1. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
2. Cheung B, Radia D, Pantedelis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia. Br J Haematol 2005;132:244-50.
3. Wolansky AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-13.
4. Antonioli E, Guglielmelli P, Pangrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-9.
5. Dotti G, Garattini E, Borleri G, Masuhara K, Spinelli O, Barbui T, et al. Leukocyte alkaline phosphatase identifies the terminally differentiated normal neutrphils and its lack in chronic myelogenous leukemia is not dependent on the p210 tyrosine kinase activity. Br J Haematol 1999;105:163-72.
6. Falanga A, Marchetti M, Balducci D. Distinct hemostatic profile of leukocytes in essential thrombcythemia (ET) carrying the JAK2 V6217F mutation. Blood 2005;106:114a[Abstract].
7. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.